Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04485767 · ClinicalTrials.gov registry record · NA

RESIST-ADT (Androgen Deprivation Therapy)

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
21
Enrollment target

NCT04485767 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04485767, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cancer undergoing androgen deprivation therapy (ADT). Our main hypothesis is that structured resistance exercise training in men undergoing ADT will preserve physical function assessed by loaded stair climbing power compared with the control group. The trial will also examine the efficacy of the exercise regimen on muscle strength, QOL and fatigue. The findings of this trial will lay the groundwork for definitive intervention trials to prevent frailty and falls in these men.

Interventions

  • BEHAVIORAL Progressive Resistance Training Exercise
  • BEHAVIORAL Flexibility and Balance Exercise

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2020-12-01
Est. Completion 2023-09-30
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04485767

The ClinicalTrials.gov registry entry for NCT04485767 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Progressive Resistance Training Exercise is the first listed.

NCT04485767 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04485767 about?

NCT04485767 is a clinical study titled "RESIST-ADT (Androgen Deprivation Therapy)". The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cancer undergoing androgen deprivation therapy (ADT). Our main hypothesis is that structured resistance exercise training in ...

What is the current status of trial NCT04485767?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2020-12-01. Estimated completion is 2023-09-30.

What interventions are being tested in trial NCT04485767?

The interventions under investigation include: Progressive Resistance Training Exercise (BEHAVIORAL), Flexibility and Balance Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT04485767?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.